Mitotane treatment for recurrent adrenocortical carcinoma following adrenalectomy

被引:0
|
作者
Garcia Dominguez, Paula [1 ]
Dibella, Andrea [1 ]
机构
[1] Southern Cty Vet specialists, Internal Med, Ringwood BH24 3JW, Hampshire, England
来源
VETERINARY RECORD CASE REPORTS | 2023年 / 11卷 / 04期
关键词
adrenalectomy; carcinoma; mitotane; PITUITARY-DEPENDENT HYPERADRENOCORTICISM; GLAND TUMORS; CANINE HYPOADRENOCORTICISM; SURGICAL-MANAGEMENT; DOGS; SURVIVAL;
D O I
10.1002/vrc2.739
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A dog was referred for investigation into polyuria and polydipsia. Investigations showed a right adrenal mass, adrenalectomy was performed, and histopathology reported a carcinoma with local invasion. Carboplatin was selected as an adjuvant chemotherapy. Initially, did not show signs of recurrence, but 9 months later the clinical signs recurred, and staging was consistent with recurrence of the carcinoma with local hepatic invasion. The mitotane ablative protocol was chosen. Our patient developed mineralocorticoid deficiency 60 days later, but never developed clinical signs of cortisol deficiency as it was started on prednisolone. Kintzer and Peterson reported that dogs with metastatic disease experienced poorer response to mitotane and shorter survival time. However, our patient responded very well, with no side effect and remission of all clinical signs. The patient is alive at time of writing this report, 10 months after starting mitotane and 22 months after diagnosis.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Kein Vorteil für adjuvante Mitotanetherapie nach Adrenalektomie beim NebennierenrindenkarzinomAdjuvant mitotane treatment after adrenalectomy is not beneficial for adrenocortical carcinoma
    H. Dralle
    Der Chirurg, 2016, 87 (11): : 980 - 980
  • [22] Clinical results of the use of mitotane for adrenocortical carcinoma
    Kasperlik-Zaluska, AA
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2000, 33 (10) : 1191 - 1196
  • [23] Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane
    Pal, Sumanta K.
    Gartrell, Benjamin
    Olsson, Carl A.
    Stein, C. A.
    ONCOLOGY-NEW YORK, 2014, 28 (07): : 624 - +
  • [24] Mitotane in adrenocortical carcinoma: a profile of its use
    Matt Shirley
    Drugs & Therapy Perspectives, 2022, 38 : 508 - 519
  • [25] Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
    Megerle, Felix
    Herrmann, Wiebke
    Schloetelburg, Wiebke
    Ronchi, Cristina L.
    Pulzer, Alina
    Quinkler, Marcus
    Beuschlein, Felix
    Hahner, Stefanie
    Kroiss, Matthias
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (04): : 1686 - 1695
  • [26] Mitotane in adrenocortical carcinoma: a profile of its use
    Shirley, Matt
    DRUGS & THERAPY PERSPECTIVES, 2022, 38 (12) : 508 - 519
  • [27] Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma
    Seki, M
    Nomura, K
    Hirohara, D
    Kanazawa, M
    Sawada, T
    Takasaki, K
    Demura, H
    ENDOCRINE-RELATED CANCER, 1999, 6 (04) : 529 - 533
  • [28] Adrenocortical carcinoma:: Surgery and mitotane for treatment and steroid profiles for follow-up
    Khorram-Manesh, A
    Ahlman, H
    Jansson, S
    Wängberg, B
    Nilsson, O
    Jakobsson, CE
    Eliasson, B
    Lindstedt, S
    Tisell, LE
    WORLD JOURNAL OF SURGERY, 1998, 22 (06) : 605 - 612
  • [29] High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
    Pape, Elise
    Feliu, Catherine
    Yelehe-Okouma, Melissa
    Colling, Natacha
    Djerada, Zoubir
    Gambier, Nicolas
    Weryha, Georges
    Scala-Bertola, Julien
    ONCOLOGIST, 2018, 23 (03): : 389 - 390
  • [30] Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells
    Maria Cristina De Martino
    Peter M. van Koetsveld
    Richard A. Feelders
    Steven W. J. Lamberts
    Wouter W. de Herder
    Annamaria Colao
    Rosario Pivonello
    Leo J. Hofland
    Endocrine, 2016, 52 : 664 - 667